According to Apellis Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.4452. At the end of 2023 the company had a P/S ratio of 17.9.
Year | P/S ratio | Change |
---|---|---|
2023 | 17.9 | -76.41% |
2022 | 75.8 | 9.63% |
2021 | 69.2 | 300.1% |
2020 | 17.3 | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |